The timing of androgen deprivation therapy (ADT) in men with relapsing but asymptomatic prostate cancer has been controversial for many years. The available evidence indicates that the current challenge is not whether immediate ADT should be the standard of care, but better selection of the men in whom it is most likely to benefit. Addition of genomic classifiers to existing prognostic indicators should improve our selection of men who will benefit from earlier use of ADT as a systemic therapy.
European urology. 2018 Jan 16 [Epub ahead of print]
Mark Frydenberg, Henry H Woo
Department of Surgery, Monash University, Melbourne, Victoria, Australia; Department of Urology, Monash Health, Melbourne, Victoria, Australia. Electronic address: ., Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, Australia; Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, Australia.